GC
GSK icon

Gratus Capital’s GSK GSK Stock Holding History

Gratus Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,959
Closed -$213K – 384
2024
Q1 		$213K Buy
+4,959
New +$205K 0.01% 305
2022
Q2 		– Sell
-5,601
Closed -$305K – 198
2022
Q1 		$305K Buy
5,601
+52
+0.9% +$2.82K 0.03% 172
2021
Q4 		$306K Buy
5,549
+61
+1% +$3.17K 0.03% 173
2021
Q3 		$262K Buy
5,488
+59
+1% +$2.96K 0.03% 169
2021
Q2 		$270K Buy
5,429
+77
+1% +$3.7K 0.03% 172
2021
Q1 		$239K Sell
5,352
-182
-3% -$8.26K 0.03% 170
2020
Q4 		$255K Buy
5,534
+56
+1% +$2.57K 0.03% 162
2020
Q3 		$258K Sell
5,478
-1,749
-24% -$87.6K 0.04% 150
2020
Q2 		$368K Buy
7,227
+61
+0.9% +$3.13K 0.06% 126
2020
Q1 		$339K Sell
7,166
-1,307
-15% -$69.7K 0.06% 136
2019
Q4 		$498K Sell
8,473
-4
-0% -$222 0.08% 132
2019
Q3 		$452K Sell
8,477
-353
-4% -$18.2K 0.07% 132
2019
Q2 		$442K Sell
8,830
-1,941
-18% -$97.4K 0.07% 132
2019
Q1 		$563K Sell
10,771
-631
-6% -$31.5K 0.09% 125
2018
Q4 		$545K Sell
11,402
-4,742
-29% -$234K 0.11% 125
2018
Q3 		$811K Sell
16,144
-1,634
-9% -$83K 0.11% 108
2018
Q2 		$896K Sell
17,778
-2,793
-14% -$141K 0.13% 103
2018
Q1 		$1M Sell
20,571
-7,227
-26% -$337K 0.14% 106
2017
Q4 		$1.23M Sell
27,798
-3,044
-10% -$141K 0.16% 103
2017
Q3 		$1.56M Buy
30,842
+576
+2% +$29.2K 0.22% 89
2017
Q2 		$1.63M Sell
30,266
-752
-2% -$40.1K 0.23% 87
2017
Q1 		$1.64M Buy
31,018
+43
+0.1% +$2.18K 0.24% 87
2016
Q4 		$1.49M Sell
30,975
-423
-1% -$20.9K 0.22% 89
2016
Q3 		$1.69M Buy
31,398
+621
+2% +$34K 0.25% 85
2016
Q2 		$1.67M Buy
30,777
+26,587
+635% +$1.4M 0.25% 83
2016
Q1 		$212K Buy
+4,190
New +$209K 0.05% 64

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Gratus Capital's GSK Position: Q2 2024 in Review

Gratus Capital sold out of GSK (GSK) in Q2 2024, closing a stake of 4,959 shares — an estimated $213K sold.

Gratus Capital first reported a position in GSK in Q1 2016 and held it in 26 quarters. The position peaked at $1.69M in Q3 2016. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • Gratus Capital reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
  • Gratus Capital sold 4,959 GSK shares in Q2 2024, an estimated $213K.
  • Gratus Capital first reported a position in GSK in Q1 2016 and held it in 26 quarters.
  • Gratus Capital's GSK position peaked at $1.69M in Q3 2016.
  • 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.